Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Rocket Pharmaceuticals Inc (NQ: RCKT ) 18.51 +0.25 (+1.37%) Streaming Delayed Price Updated: 12:47 PM EDT, Aug 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 233,940 Open 18.75 Bid (Size) 18.50 (2) Ask (Size) 18.56 (4) Prev. Close 18.26 Today's Range 18.46 - 19.01 52wk Range 14.89 - 32.52 Shares Outstanding 65,837,894 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News RCKT Stock Earnings: Rocket Pharmaceuticals Misses EPS for Q2 2024 August 05, 2024 RCKT stock results show that Rocket Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress August 05, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire Performance YTD -37.25% -37.25% 1 Month -17.92% -17.92% 3 Month -21.77% -21.77% 6 Month -35.95% -35.95% 1 Year +13.98% +13.98% More News Read More FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides June 28, 2024 Via Benzinga Exposures Product Safety Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session June 28, 2024 Via Benzinga Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel) June 28, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire Analyst Ratings for Rocket Pharmaceuticals November 07, 2023 Via Benzinga These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains June 14, 2024 Via Talk Markets Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy May 29, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) May 10, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire RCKT Stock Earnings: Rocket Pharmaceuticals Beats EPS for Q1 2024 May 06, 2024 Via InvestorPlace Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress May 06, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia April 02, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team March 26, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress February 26, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) February 13, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire 7 Speculative Stocks to Double Your Money THIS Year January 22, 2024 Via InvestorPlace Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Rocket Pharmaceuticals, Inc. Via Business Wire Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors December 12, 2023 From Rocket Pharmaceuticals, Inc. Via Business Wire Merit Medical Systems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session December 05, 2023 Via Benzinga Topics Stocks Exposures US Equities Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress November 06, 2023 From Rocket Pharmaceuticals, Inc. Via Business Wire Rocket Pharmaceuticals Stock Sees Improved Price Strength November 02, 2023 Via Investor's Business Daily Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher October 27, 2023 Via Investor's Business Daily Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) October 19, 2023 From Rocket Pharmaceuticals, Inc. Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023 October 24, 2023 Via Benzinga Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) October 02, 2023 From Rocket Pharmaceuticals, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
